In vivo dilation of fetal and neonatal ductus arteriosus by inhibition of phosphodiesterase-5 in rats

Pediatric Research

Volumn 58, Issue 1, 2005, Pages 42-45

  Momma, Kazuo ^a   Toyoshima, Katsuaki ^a,b   Imamura, Shinichiro ^a   Nakanishi, Toshio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL DIAMETER; DISEASE COURSE; DRUG EFFECT; DRUG SENSITIVITY; DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS OBLITERATION; ENZYME INHIBITION; FETUS; FREEZING; IN VITRO STUDY; IN VIVO STUDY; MICROTOME; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; TREATMENT OUTCOME; VASODILATATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; CYCLIC GMP; DUCTUS ARTERIOSUS; FREEZING; INDOMETHACIN; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PROSTAGLANDINS E; RATS; RATS, WISTAR; TIME FACTORS;

EID: 22044442963     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000156370.50874.3C     Document Type: Article

References (20)

1. Rudolph AM 2001 Congenital Diseases of the Heart, 2nd Ed. Futura, Armonk, pp 155-196
2. Rudolph AM 2003 Fetal circulation. In: Yagel S, Silverman NH, Gembrach U (eds) Fetal Cardiology. Martin Dunitz, London, pp 107-120
3. Momma K 2004 Fetal and neonatal ductus arteriosus. In: Curtis-Prior P (ed) The Eicosanoids. John Wiley & Sons, Chichester, pp 569-581
4. Moor P, Brook MM, Heymann MA 2001 Patent ductus arteriosus. In: Allen HD, Gutgesell HP, Clark EB, Driscoll DJ (eds) Moss Adams Heart Disease in Infants, Children, and Adolescents, 6th Ed. Lippincott Williams & Wilkins, Philadelphia, pp 652-569
5. Corbert AJ 1998 Medical manipulation of the ductus arteriosus. In: Garson A Jr, Bricker JT, Fisher DJ, Neish SR (eds) The Science and Practice of Pediatric Cardiology, 2nd Ed. Williams & Wilkins, Baltimore, pp 2489-2513
6. Clyman RI 1990 Developmental physiology of the ductus arteriosus. In: Long WA (eds) Fetal & Neonatal Cardiology. Saunders, Philadelphia, pp 64-75
7. Momma K, Toyono M 1999 The role of nitric oxide in dilating the fetal ductus arteriosus in rats. Pediatr Res 46:311-315
8. Walsh RS, Mentzer RM Jr 1987 Role of cyclic nucleotides in relaxation of fetal lamb ductus arteriosus. Surgery 102: 313-318
9. Beavo JA 1995 Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748
10. Jackson G, Benjamin N, Jackson N, Allen MJ 1999 Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83:13C-20C
11. 2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BKca channels. Pediatr Res 52:19-24
12. Momma K, Nakanishi T, Imamura S 2003 Inhibition of in vivo constriction of fetal ductus arteriosus by endothelin receptor blockade in rats. Pediatr Res 53:479-485
13. Momma K, Nishihara S, Ota Y 1981 Constriction of the fetal ductus arteriosus by glucocorticoid hormones. Pediatr Res 15:19-21
14. Momma K, Konishi T, Hagiwara H 1985 Characteristic morphology of the constricted fetal ducts arteriosus following maternal administration of indomethacin. Pediatr Res 19:493-500
15. Wallenstein S, Zucker CL, Fleiss JL 1980 Some statistical methods useful in circulation research. Circ Res 47:1-9
16. Zusman RM 1999 Cardiovascular data on sildenanl citrate. Introduction. Am J Cardiol 83:1C-2C
17. Gillies HC, Roblin D, Jackson G 2002 Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 86:131-141
18. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S 2002 Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary artery hypertension: comparison with inhaled nitric oxide. Circulation 105:2398-2403
19. Wallis RM 1999 The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Nippon Yakurigaku Zasshi 114(suppl 1):22p-26p
20. Rybalkin SD. Yan C, Bornfeldt KE, Beavo JA 2003 Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291